Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H L McLeod

Showing results (1-10 of 156) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction?H L McLeod
Nature Genetics|November 1, 2001
Pharmacogenetics: more than skin deepH L McLeod
European Journal of Clinical Pharmacology|January 1, 1995
Commentary on interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT) activityH L McLeod
Lancet (London, England)|January 26, 2002
Pharmacokinetic differences between ethnic groupsH L McLeod
The New England Journal of Medicine|September 8, 2001
Race and responsiveness to drugs for heart failureH L McLeod
British Journal of Clinical Pharmacology|July 15, 1998
Clinically relevant drug-drug interactions in oncologyH L McLeod
Clinical Pharmacology and Therapeutics|October 1, 1994
Concordance of phenotype and genotype for CYP2D6H L McLeod
Pharmacology & Therapeutics|January 1, 1997
Therapeutic drug monitoring opportunities in cancer therapyH L McLeod
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
Strategies for enzyme/prodrug cancer therapyG Xu, H L McLeod
British Journal of Cancer|January 8, 2004
Cancer pharmacogeneticsS Marsh, H L McLeod
Pageof 16

Showing results (1-10 of 156) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction?H L McLeod
Nature Genetics|November 1, 2001
Pharmacogenetics: more than skin deepH L McLeod
European Journal of Clinical Pharmacology|January 1, 1995
Commentary on interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT) activityH L McLeod
Lancet (London, England)|January 26, 2002
Pharmacokinetic differences between ethnic groupsH L McLeod
The New England Journal of Medicine|September 8, 2001
Race and responsiveness to drugs for heart failureH L McLeod
British Journal of Clinical Pharmacology|July 15, 1998
Clinically relevant drug-drug interactions in oncologyH L McLeod
Clinical Pharmacology and Therapeutics|October 1, 1994
Concordance of phenotype and genotype for CYP2D6H L McLeod
Pharmacology & Therapeutics|January 1, 1997
Therapeutic drug monitoring opportunities in cancer therapyH L McLeod
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
Strategies for enzyme/prodrug cancer therapyG Xu, H L McLeod
British Journal of Cancer|January 8, 2004
Cancer pharmacogeneticsS Marsh, H L McLeod
Pageof 16